 The purpose of Part 1 of the study is to determine the safety of the combination of Siltuximab CNTO 328 and bortezomib Velcade. The purpose of Part 2 of the study is to compare the length of progression free survival for those patients given CNTO 328 and bortezomib to those patients given bortezomib alone. 